Pfizer Unit Wins $107.5M Patent Verdict Against AstraZeneca
By Bonnie Eslinger · May 17, 2024, 8:26 PM EDT
A Delaware federal jury on Friday said that AstraZeneca Pharmaceuticals LP should pay $107.5 million in royalty damages for infringing a Pfizer-brand cancer treatment patent, although a final decision won't be issued...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login